Logo
x

Search

Subscribe Now

HER2-Overexpressing

Samsung Bioepis Launches Ontruzant (trastuzumab- biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

Samsung Bioepis Launches Ontruzant (trastuzumab- biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

  • August 11, 2020
Celltrion and Teva's Herzuma (trastuzumab-pkrb- Herceptin biosimilar) Receives FDA's Approval for HER2-Overexpressing Breast Cancer

Celltrion and Teva's Herzuma (trastuzumab-pkrb- Herceptin biosimilar) Receives FDA's Approval for HER2-Overexpressing Breast Cance...

  • December 14, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.